XML 13 R48.htm IDEA: XBRL DOCUMENT v2.4.0.8
Segmental Reporting (Tables)
3 Months Ended
Mar. 31, 2014
Segment Reporting [Abstract]  
Schedule of Segment Revenue from Major Products
 3 months to,3 months to,
 March 31,March 31,
 20142013
 $’M$’M
 ______________________
   
VYVANSE351.2298.4
LIALDA/MEZAVANT128.9100.5
ELAPRASE128.6114.3
REPLAGAL114.3114.0
VPRIV86.981.6
CINRYZE85.6-
ADDERALL XR85.199.8
INTUNIV82.377.7
FIRAZYR74.941.7
PENTASA72.371.0
FOSRENOL41.442.3
XAGRID27.123.4
Other product sales29.533.5
 ________________________
Total product sales1,308.11,098.2
 ________________________